Navigation Links
Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths
Date:12/15/2008

Study confirms effectiveness of widely used approach, experts say

MONDAY, Dec. 15 (HealthDay News) -- Men with locally advanced prostate cancer -- cancer that has spread beyond the wall of the prostate gland -- who undergo radiation plus long-term hormone treatment cut their risk of dying in half, a new study has found.

The addition of radiotherapy kept patients healthy much longer, the Swedish research team concluded. In fact, by adding radiotherapy, men's overall survival was increased by 10 percent with only a modest increase in the risk of radiation-related side effects.

"The study will change practice in the treatment of locally advanced or local aggressive prostate cancer," said lead researcher Dr. Anders Widmark, from the department of radiation sciences and oncology at Umeå University. "These patients should be offered the addition of local radiation treatment."

At least one American expert agreed. "This study just proves what we have suspected for a long time -- namely, that both treatments are needed to get the best results," said Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston.

The report is published in the Dec. 16 online edition of The Lancet.

In this trial, 875 men with locally advanced prostate cancer were randomly assigned to receive either the drug flutamide (Eulexin), to block androgens (male hormones), or hormone therapy along with radiation. Androgens are thought to encourage the spread of prostate cancer, so blocking their effect is a common prostate cancer treatment.

Over an average follow-up of almost eight years, 79 men who received hormone treatment alone died, compared with 37 men who received hormone treatment plus radiation, Widmark's group found.

After 10 years, 23.9 percent of the men in the hormone therapy-only group had died from prostate cancer compared with 11.9 percent of the men in the combined treatment group. In addition, death from any cause was higher in the hormone therapy-only group, (39.4 percent) than in the combined treatment group (29.6 percent), the researchers found.

Moreover, fewer men in the combined treatment group saw a return of their cancer (26 percent) than did men in the hormone-only group (75 percent).

The addition of local treatment with radiotherapy improves survival, Widmark concluded. "These patients are highly curable -- only 10 percent will die of prostate cancer within 10 years," he said. "They should not give up."

Dr. Chris Parker, from the Institute of Cancer Research in Sutton, Surrey, UK, and author of an accompanying editorial in the journal, said that combined radiation and hormone therapy should become standard treatment for men with locally advanced prostate cancer.

"This is a pivotal trial that for the first time demonstrates that radiotherapy improves survival of men with high-risk localized and locally advanced prostate cancer," Parker said. "It is no longer acceptable to regard hormone therapy alone as standard of care."

D'Amico agreed, noting that most U.S. doctors already provide combo therapy as standard treatment for men with locally advanced prostate cancer.

"Combined treatment with radiation and hormonal therapy is necessary to get the best overall survival in men with locally advanced prostate cancer," he said. "The study nails that home."

More information

For more information on prostate cancer, visit the American Cancer Society .



SOURCES: Anders Widmark, M.D., Ph.D., Department of Radiation Sciences, Oncology, Umeå University, Sweden; Chris Parker, M.D., Institute of Cancer Research, Sutton, Surrey, UK; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; Dec. 16, 2008, online edition, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Angled gantry technique reduced breast radiation exposure by 50 percent
2. Preoperative radiation may improve survival rates in advanced rectal cancer patients
3. Delays in radiation therapy lead to increased breast cancer recurrence
4. Radiation before surgery improves pancreatic cancer outcomes
5. Mammogram most effective 12 months after radiation treatment
6. Type of breast reconstruction impacts radiation therapy outcomes
7. Partial Breast Irradiation Now Provided by Rocky Mountain Oncology Center
8. New model developed to estimate radiation skin doses during CT-guided interventional procedures
9. Premier Radiation Oncology Meeting Breaks Attendance, Exhibit Space Record at Boston Meeting
10. Radiation Oncology Experts from 16 Countries Attend Technical University of Munich's International Conference on TomoTherapy
11. Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: